Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relacorilant open-label extension in endogenous Cushing syndrome
2024-514079-17-00Phase 3Authorised
- Sponsor
- Corcept Therapeutics
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of relacorilant in endogenous Cushing's syndrome, sponsored by Corcept Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events, Change from baseline in clinical laboratory tests and 3 more. Planned start Sep 2024; status: authorised.
02
Drugs
relacorilant
03
Conditions
endogenous Cushing's syndrome
Beyond the preview
Go deeper on 2024-514079-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514079-17-00.